The nation of Zimbabwe has rejected a significant American healthcare agreement valued at 367 million US dollars (£272m) over five years because of Washington's demand for confidential data.
The decision was revealed after a official document dated December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesperson later stated that the United States was seeking health data for scientific study and commercial purposes while was unwilling to share the benefits from any future vaccines.
"We will now turn to the difficult and regrettable process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for continued talks to find a deal acceptable to all parties so the nation's vital HIV treatment initiative can proceed.
Broader Implications
This rejection follows a similar situation in neighbouring Kenya, where a high court halted a similar deal with the US after legal challenges were filed about the safety of citizens' health data.
After returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government deals to enhance transparency and responsibility.
As per reports, 16 African countries have to date agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, without any equivalent promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Put simply, our country would provide the basic resources for scientific discovery with no assurance that the end products would be accessible to our citizens if a new pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of bilateral health agreements were undermining systems already established through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This framework is intended to guarantee that when a nation provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
These objections over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how subsequent co-operation might be designed in a way that respects the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the official position, but recommended that negotiations should continue given that a large portion of the country's Aids initiatives relied on external financing.
"In cases where specific concerns arise, including those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The situation highlights the complex tensions between receiving much-needed foreign assistance and safeguarding local interests in an ever more data-driven world.